Brought to you by 
BioXell and Merck partner to develop sepsis candidates
03 Jun 2005
Executive Summary
Italian pharmaceutical company BioXell SPA (spun out from Roche in 2002) has signed on Merck & Co. to exclusively develop therapeutics and diagnostics related to its TREM (Triggering Receptors Expressed on Myeloid cells) class of receptors. The agreement will initially focus on sepsis, but may also be expanded to include other inflammation indications.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioXell and Merck partner to develop sepsis candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice